Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3389354 | 0.88 | GRIN2D (0.47) | HRH3DRD2HTR1ADRD1HTR2A | |
| SCHEMBL3389303 | 0.87 | GRIN2D (0.46) | HRH3DRD2HTR1ADRD1HTR2A | |
| SCHEMBL3389754 | 0.85 | ALDH1A1 (0.44) | DRD2HTR1ADRD1HTR2ADRD3 | |
| SCHEMBL3921129 | 0.85 | CYP2D6 (0.46) | HRH3DRD2HTR1AHTR2A | |
| SCHEMBL3388497 | 0.84 | HRH3 (0.40) | HRH3HRH1ACHE | |
| SCHEMBL3386757 | 0.84 | HRH3 (0.38) | MAPTHRH3DRD2HRH1ACHE | |
| SCHEMBL3386240 | 0.84 | DRD2 (0.44) | HRH3DRD2DRD3 | |
| SCHEMBL3384766 | 0.83 | HRH3 (0.41) | HRH3HRH1ACHE | |
| SCHEMBL3386229 | 0.83 | HRH3 (0.41) | HRH3HRH1ACHE | |
| SCHEMBL3387503 | 0.83 | HRH3 (0.43) | HRH3DRD2HTR1ADRD1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258861-A1 | Tetrahydronaphthyridine Derivatives | LUNN GRAHAM | 2009-10-15 | — | — | US | claimed |
| US-7557121-B2 | Tetrahydronaphthyridine derivatives | PFIZER INC (US) | 2009-07-07 | — | — | US | claimed |
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | LUNN GRAHAM | 2005-11-17 | — | — | US | claimed |
| EP-1756104-B1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | PFIZER LTD (GB) | 2010-12-15 | — | — | EP | disclosed |
| US-20090258861-A1 | Tetrahydronaphthyridine Derivatives | LUNN GRAHAM | 2009-10-15 | — | — | US | disclosed |
| US-20090258861-A1 | Tetrahydronaphthyridine Derivatives | LUNN GRAHAM | 2009-10-15 | — | — | US | disclosed |
| US-7557121-B2 | Tetrahydronaphthyridine derivatives | PFIZER INC (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557121-B2 | Tetrahydronaphthyridine derivatives | PFIZER INC (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557121-B2 | Tetrahydronaphthyridine derivatives | PFIZER INC (US) | 2009-07-07 | — | — | US | disclosed |
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | LUNN GRAHAM | 2005-11-17 | — | — | US | disclosed |
| EP-1595881-A1 | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands | Pfizer Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | HRH4, HRH3, HRH1 | LMNA 3049/4885TP53 4508/4885MAPT 1644/4885 |
| US-20090258861-A1 | Tetrahydronaphthyridine Derivatives | HRH4, HRH3, HRH1 | LMNA 3049/4885TP53 4508/4885MAPT 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.